Kiniksa Pharmaceuticals International PLC
KNSA35.580USD
+0.150+0.42%
交易中 （美东）报价延迟15分钟
2.63B总市值
549.91市盈率 TTM
关于 Kiniksa Pharmaceuticals International PLC 公司
Kiniksa Pharmaceuticals International, plc 是一家商业阶段的生物制药公司，专注于发现、收购、开发和商业化治疗药物，用于治疗患有严重衰弱性疾病且医疗需求未得到满足的患者。其免疫调节资产组合 ARCALYST、abiprubart 和 mavrilimumab 基于强大的生物学原理或经过验证的机制，针对一系列医疗资源不足的心血管和自身免疫疾病，并具有差异化潜力。ARCALYST 是一种白细胞介素-1α 和白细胞介素-1β 细胞因子诱捕器。ARCALYST 用于治疗复发性心包炎并降低成人和 12 岁及以上儿童的复发风险。 ARCALYST 还被批准用于治疗冷吡啉相关周期性综合征 (CAPS)，包括家族性冷自身炎症综合征 (FCAS) 和 Muckle-Wells 综合征，以及维持白细胞介素-1受体拮抗剂缺乏症的缓解。
公司简介
公司代码KNSA
公司名称Kiniksa Pharmaceuticals International PLC
上市日期May 24, 2018
CEOMr. Sanjiv K. (Sanj) Patel
员工数量315
证券类型Ordinary Share
年结日May 24
公司地址23 Old Bond Street, Floor 3
城市LONDON
上市交易所NASDAQ Global Select Consolidated
国家United Kingdom
邮编WIS 4PZ
电话
网址https://www.kiniksa.com/
公司代码KNSA
上市日期May 24, 2018
CEOMr. Sanjiv K. (Sanj) Patel
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
221.59K
+7.32%
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
84.51K
--
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
61.32K
+6.83%
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
34.55K
-14.08%
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
31.09K
+15.09%
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
24.21K
+63.16%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
18.47K
+6.34%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Independent Director
Independent Director
12.55K
+33.85%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
12.55K
--
Mr. Ross Moat
Mr. Ross Moat
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
9.41K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
221.59K
+7.32%
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
84.51K
--
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
61.32K
+6.83%
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
34.55K
-14.08%
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
31.09K
+15.09%
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
24.21K
+63.16%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Rubric Capital Management LP
8.99%
The Vanguard Group, Inc.
7.19%
Baker Bros. Advisors LP
6.50%
Tang Capital Management, LLC
5.36%
Fairmount Funds Management LLC
4.08%
其他
67.89%
持股股东
持股股东
占比
Rubric Capital Management LP
8.99%
The Vanguard Group, Inc.
7.19%
Baker Bros. Advisors LP
6.50%
Tang Capital Management, LLC
5.36%
Fairmount Funds Management LLC
4.08%
其他
67.89%
股东类型
持股股东
占比
Hedge Fund
44.37%
Investment Advisor/Hedge Fund
23.83%
Investment Advisor
19.43%
Research Firm
4.64%
Individual Investor
3.81%
Pension Fund
0.47%
Bank and Trust
0.19%
Family Office
0.11%
Insurance Company
0.07%
其他
3.08%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
396
42.64M
98.10%
-1.50M
2025Q1
407
42.98M
101.69%
-650.43K
2024Q4
391
41.95M
99.92%
-5.07M
2024Q3
382
42.52M
104.55%
-472.80K
2024Q2
354
38.32M
94.71%
-9.35M
2024Q1
340
41.61M
104.40%
+110.03K
2023Q4
319
36.70M
103.36%
-5.01M
2023Q3
318
37.56M
105.96%
-4.22M
2023Q2
312
35.54M
100.99%
-4.88M
2023Q1
303
35.17M
100.37%
-5.41M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Rubric Capital Management LP
3.38M
7.99%
+764.14K
+29.18%
Mar 31, 2025
The Vanguard Group, Inc.
3.35M
7.91%
+151.60K
+4.74%
Mar 31, 2025
Baker Bros. Advisors LP
2.82M
6.66%
--
--
Mar 31, 2025
Tang Capital Management, LLC
2.12M
5%
+1.49M
+237.03%
Mar 31, 2025
Fairmount Funds Management LLC
1.10M
2.6%
+1.10M
--
Mar 31, 2025
Acadian Asset Management LLC
1.03M
2.44%
+651.70K
+170.33%
Mar 31, 2025
Braidwell LP
1.96M
4.64%
-1.49M
-43.14%
Mar 31, 2025
Desnick (Robert)
1.05M
2.48%
--
--
Apr 08, 2025
Millennium Management LLC
847.12K
2%
+67.45K
+8.65%
Mar 31, 2025
Pictet Asset Management Ltd.
1.13M
2.68%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
Global X Russell 2000 Covered Call ETF
0%
Vanguard US Multifactor ETF
0%
Fidelity Small-Mid Multifactor ETF
0%
Global X Russell 2000 Covered Call ETF
占比0%
Vanguard US Multifactor ETF
占比0%
Fidelity Small-Mid Multifactor ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
